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Abstract
Background: Oropharyngeal cancer is an important, understudied cancer affecting Aboriginal and Torres Strait Islander
Australians. The human papillomavirus (HPV) is a significant risk factor for oropharyngeal cancer. Current generation HPV
vaccines are effective against the 2 most common types of high-risk HPVs in cancer (hrHPVs 16/18).
Objectives: This study aims (1) to yield population estimates of oncogenic genotypes of HPV in the mouth and oropharynx of
defined Aboriginal and Torres Strait Islander populations; (2) to estimate the proportion of oropharyngeal cancer attributable to
HPV among these Australian citizens; (3) to estimate the impact of HPV vaccination as currently implemented on rates of
oropharyngeal cancer among Aboriginal and Torres Strait Islander Australians; and (4) taking into account impact on oropharyngeal
as well as cervical cancer, to evaluate efficacy and cost-effectiveness of targeted extended HPV vaccination to older ages, among
our study population.
Methods: Our study design and operation is straightforward, with minimal impost on participants. It involves testing for carriage
of hrHPV in the mouth and oropharynx among 1000 Aboriginal South Australians by simple saliva collection and with follow-up
at 12 and 24 months, collection of sexual history at baseline, collection of information for estimating health state (quality-of-life)
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utilities at baseline, genotyping of viruses, predictive outcome and cost-effectiveness modeling, data interpretation and development
of vaccination, and follow-up management strategies driven by the Aboriginal community.
Results: Participant recruitment for this study commenced in February 2018 and enrollment is ongoing. The first results are
expected to be submitted for publication in 2019.
Conclusions: The project will have a number of important outcomes. Synthesis of evidence will enable generation of estimates
of the burden of oropharyngeal cancer among Aboriginal and Torres Strait Islander Australians and indicate the likely effectiveness
and cost-effectiveness of prevention. This will be important for health services planning, and for Aboriginal health worker and
patient education. The results will also point to important areas where research efforts should be focused to improve outcomes
in Aboriginal and Torres Strait Islander Australians with oropharyngeal cancer. There will be a strong focus on community
engagement and accounting for the preferences of individuals and the community in control of HPV-related cancers. The project
has international relevance in that it will be the first to systematically evaluate prevention of both cervical and oropharyngeal
cancer in a high-risk Indigenous population taking into account all population, testing, and surveillance options.
Registered Report Identifier: RR1-10.2196/10503
(JMIR Res Protoc 2018;7(6):e10503)   doi:10.2196/10503
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Introduction
Human Papilloma Viruses
Human papillomaviruses (HPVs) are a heterogeneous group of
over 100 genotypes, being circular, double-stranded DNA
viruses that grow in stratified epithelia of skin and mucous
membranes. There are approximately 15 HPV types that have
potential to cause cancer. Before implementation of vaccination,
a restricted number of these genotypes, known as high risk or
oncogenic types, were the most common sexually transmitted
infection in Australia, with an estimated 4 out of 5 Australians
having a high-risk HPV (hrHPV) infection at some point in their
lives [1]. The most common hrHPV types are HPV-16 and
HPV-18. These HPVs are a precursor to a range of cancers in
both females and males (particularly cervical cancer, other
anogenital cancers and oropharyngeal cancer) and are usually
acquired within 2-5 years of commencing sexual activity [2].
Preventing such HPV infections is a public health priority to
reduce cancer and HPV-associated complications [3].
The rate of carriage of hrHPV at a population level at sites
relevant to cancer (anogenital and oropharyngeal) in Australia
is difficult to characterize; most surveys have not been national
or representative, and almost all have focused on females only.
Although there are some general population oral HPV DNA
prevalence data [4], the big gap in the knowledge base is the
oral and oropharyngeal HPV prevalence in a high-risk group
for oropharyngeal cancers, Aboriginal and Torres Strait Islander
Australians [5].
Human Papillomavirus and Cervical Cancers
Cervical cancer is the fourth most common cancer of women
internationally [6]. Virtually, all cervical cancers are attributable
to infection with oncogenic genotypes of HPV [7]. In an
international study, incidence of cervical cancer was found to
be higher among Indigenous women than among non-Indigenous
women in most countries (Australia, New Zealand, Canada, and
the United States) [8]. In Australia, there are undisputedly higher
rates of cervical cancer and mortality among Indigenous
compared with non-Indigenous women [9].
Human Papillomavirus and Oropharyngeal Cancers
Oropharyngeal cancers include cancer of the middle part of the
throat: the tonsils, posterior one-third of the tongue, and lateral
and posterior walls of the oropharynx [10]. Approximately 90%
of oropharyngeal cancers are squamous cell carcinomas [11].
Tobacco and heavy alcohol use, often in a background of diets
poor in essential antioxidant vitamins and minerals, are major
risk factors [12]. The impact of tobacco and alcohol is
synergistic, ie, a person exposed to both has multiplicative, not
just additive, risk [13]. Additional risk indicators include being
male, older age, having infection with Candida or a
pro-inflammatory bacteriale, or a compromised immune system
[14,15]. Survival from oropharyngeal cancers is comparatively
low. This is because they are frequently asymptomatic and
diagnosed at a late stage. In general, more than half of all
persons with oropharyngeal cancer have regional or distant
metastases at diagnosis [16]. Once the cancer has metastasized,
prognosis is worse than when localized. Relative 5-year survival
in the United States is 82% for localized disease, 56% for
regional lymph node spread, and 33% for distant metastases
[17].
In addition to tobacco and alcohol, HPV has been increasingly
identified as a significant risk factor for oropharyngeal cancer
[18]. Both oral HPV prevalence and HPV-positive
oropharyngeal cancers are associated with younger age
(compared with tobacco and alcohol-related oropharyngeal
cancer), sex (higher incidence in males), sexual behaviors
(higher among those who have ever had oral sex), and number
of sexual partners (applies particularly to men, but works both
ways) [19]. These factors increase the risk of cancer
development 3-to 5-fold [20]. The proportion of oropharyngeal
cancers that are HPV-positive has increased over the last decade
in Europe and North America to an estimated 70% [21].
Indicative data from Australia suggest a similar increase in the
fraction of oropharyngeal cancers that might be attributable to
HPV [22].
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Burden of Oropharyngeal Cancer in Australia
Head and neck cancers (of which oropharyngeal cancer is one)
have been described as being more emotionally traumatic than
any other form of cancer [23,24]. Treatments can be debilitating
and disfiguring, with patients frequently going on to live with
chronic functional impairment in a range of areas including
speech and swallowing [25]. There are substantial effects on
oral health and nutrition [26], on social functioning, and on
mood, with an often immediate decrease in health-related quality
of life which persists long term [24]. Ariyawardana and Johnson
reported that, although rates of overall lip, oral cavity, and
oropharyngeal cancer declined between 1982 and 2008,
presumably due to decreased alcohol and tobacco use, and
potentially improved sun protection for lip cancer, they were
still high [11]. When considered in isolation, rates of
oropharyngeal cancer increased during this time (1.2% per
annum for men, 0.8% per annum for females), possibly due to
an increased incidence of HPV-related oropharyngeal cancer
[11]. Hong reported that the proportion of oropharyngeal cancers
which were positive for HPV DNA and p16 increased from
20.2% in 1987-1995 to 63.5% in 2006-2010 [27].
Oropharyngeal Cancer in Aboriginal and Torres Strait
Islander Australians
There is little documented evidence on the incidence of
oropharyngeal cancer among Aboriginal and Torres Strait
Islander Australians at a national level. Johnson and colleagues
reported that Indigenous persons living in Queensland (who
comprise 4% of the Queensland population) were more likely
than the total Queensland population to be diagnosed with
certain head and neck cancers between 1997 and 2012,
specifically base of tongue or tonsil or oropharynx (standardized
incidence ratio=2.16; n=81) [5]. Five-year cause-specific
survival estimates, adjusted for age and sex, were 75% (95%
CI 74-76%) for non-Indigenous persons and 43% (95% CI
38-49%) for Indigenous persons. Similar differentials in survival
were observed for cancers of the base of
tongue/tonsil/oropharynx (64% vs 27%) and mouth/oral cavity
(66% vs 42%) [28]. In 2003, the rate ratio of disability-adjusted
life years due to oral cavity and oropharyngeal cancer among
Aboriginal and Torres Strait Islander Australians was 3.8 times
that reported for the total Australian population [29].
Oropharyngeal Cancer Risk Factors Among
Indigenous Australians
As with the general population, alcohol and tobacco use are
often cited to be significant risk factors for oropharyngeal cancer
among Aboriginal and Torres Strait Islander Australians,
although the population attributable fraction for HPV-related
oropharyngeal cancers in this group is unknown [9]. Aboriginal
and Torres Strait Islander Australians generally commence
tobacco smoking at an earlier age, continue to smoke for longer,
and make fewer quitting attempts than non-Indigenous
Australians [30]. In 2012-2013, Aboriginal and Torres Strait
Islander Australians were 2.6 times more likely than
non-Indigenous Australians to be current daily smokers (40%
compared with 15% after age standardization) [31].
High-Risk Human Papillomavirus Among Aboriginal
and Torres Strait Islander Australians
There are currently no population estimates of carriage of hrHPV
in the upper aero-digestive tract among Aboriginal and Torres
Strait Islander Australians. This is a substantial deficit in the
contemporary knowledge base, particularly given the higher
risk for oropharyngeal cancer among this population. To
determine prevalence of hrHPV, and risk factors associated with
the infection among this population, data on prevalence using
sensitive HPV detection methods are necessary.
Efficacy of Human Papillomavirus Vaccination
Prevention of acquiring a persistent infection with a hrHPV
through vaccination is a cost-effective and life-saving
intervention to decrease the burden of HPV-related cancers in
Australia. Current bi- or trivalent vaccines are effective against
the 2 genotypes most strongly associated with cancer (types 16
and 18), which are detected in approximately 95% of
HPV-positive oropharyngeal tumors in the United States [32,33],
94% of HPV-positive oropharyngeal tumors in males in
Australia [27], and approximately 70% of cervical cancer
worldwide. HPV vaccination in Australia is currently provided
free of charge to adolescents aged 12-13 years through a
school-based program. The goal of early vaccination is to
immunize before first exposure to hrHPV [34]. The efficacy
and immunogenicity of hrHPV vaccines have proven excellent
in several phase 2 and 3 trials involving tens of thousands of
women [35]. Few subjects lost their antibodies during the 5-6
years after vaccination, with no breakthrough disease occurring
among these individuals. There has been a move to a 2-dose
vaccination, which means the effective vaccine coverage in the
National HPV Vaccination Program Register in Australia is
likely to go up (easier to deliver in 2 rather than 3 doses),
although dose spacing is very important. The next generation
of nonavalent vaccines [36] has also been approved and is
currently under review. Importantly, there is now a growing
body of evidence that current vaccines prevent HPV infection
at noncervical sites, including the mouth and oropharynx
[37,38].
Human Papillomavirus Vaccination Uptake in
Indigenous Populations
There are no national-level data available for the uptake of HPV
vaccination among Aboriginal and Torres Strait Islander
Australians. Data from the first stage of the National HPV
Vaccination Program (NHVP) suggest that, in Queensland,
coverage among Indigenous girls aged 12-17 years compared
with all girls aged 12-17 years was lower with each dose (lower
by 4% for dose 1, 10% percent for dose 2, and 15% for dose
3). This pattern was not seen in the Northern Territory, where
initial coverage was 17% lower among Indigenous girls, but
the course completion rate among those who started vaccination
was identical (84%) [39]. Both used data on genital warts, and
both reported that the impact of HPV vaccination appeared to
be at least as strong in young Indigenous Australians as in
non-Indigenous Australians [40,41]. Although there were
initially catch-up phases of the NHVP that offered publicly
funded vaccination to females aged up to age 26 years and boys
aged up to 15 years, these ceased in 2009 and 2014, respectively.
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There is now a relatively narrow window in early adolescence
when individuals can receive free vaccination; otherwise, the
remainder or full vaccine course incurs an additional cost
(approximately Aus $150 per dose). This is likely to be a
substantial barrier to uptake among Aboriginal and Torres Strait
Islander Australians, as is the possibility of culturally
inappropriate, insensitive, alienating, or intimidating aspects of
provision in broader health care services [42]. It is worth
highlighting, however, that school-based vaccinations reduce
disparities, with school retention rates among Indigenous
preadolescents being reasonably high at age 12 to 13 years [43].
Efficacy of Human Papillomavirus Vaccination in
Older Populations
Wheeler and colleagues [44] conducted a phase 3, double-blind,
randomized controlled trial among healthy women older than
25 years to test the hypothesis that the HPV 16/18 vaccine would
be efficacious in protecting against infections, cytological
abnormalities, and lesions associated with HPV 16/18 and
cervical intraepithelial neoplasia level 1+, irrespective of HPV
type, and infection with nonvaccine types HPV 31 and HPV
45. After 7 years of follow-up, their hypothesis was proved
correct. HPV vaccination is available to females aged up to 45
years and males aged up to 26 years in Australia, at a cost. The
level of elective uptake in females who were not eligible to
receive vaccination through the publicly funded program is low
(11%) [45].
Cost-Effectiveness of Human Papillomavirus
Vaccination
Although population-level impact and herd effects following
HPV vaccination have been widely documented,
cost-effectiveness evaluations in Australia are scarce.
Kulasingam et al reported on the cost-effectiveness for females,
which supported the original Commonwealth Serum
Laboratories application for the vaccine to be included on the
National Immunization Program [46]. The cost-effectiveness
evaluations that supported HPV vaccination for boys have never
been published, although Smith and colleagues [47] evaluated
the herd immunity benefits and incremental impact of male
vaccinations on cancer, whereas Simms et al [48] evaluated
whether cervical screening would remain cost-effective in
women offered the next generation nonavalent HPV vaccine in
4 developed countries. To the best of our knowledge, there have
been no specific cost-effectiveness evaluations of the optimal
strategies for HPV vaccination in Indigenous populations
(including the potential for extending vaccination to older
ages)—a critical gap in the knowledge base given the higher
burden of oropharyngeal and cervical cancer risk among this
group.
What Are Utilities and Why Are They Important?
Utilities are fundamental values that represent the strength of
an individual’s preferences for specific health-related outcomes.
Measuring health utilities involves 2 main steps: defining a set
of health states of interest and valuing those health states. It is
important to estimate utilities in relation to HPV, cervical cancer,
and oropharyngeal cancer among Aboriginal and Torres Strait
Islander Australians because the frame of reference regarding
prevention, screening, and burden of cancer treatment is likely
to differ in meaningful ways compared with the non-Indigenous
population. Differences may be because of the substantial travel
required for many Indigenous Australians and because of time
away from family and country. There may be inherent distrust
and fear of hospital systems not apparent in non-Indigenous
populations, and the specific treatment-associated morbidity
may be valued differently. It is important to capture this
information that can be used to directly calculate
quality-adjusted life years and to, in turn, be translated into
health policy regarding Aboriginal patient journeys with primary
and secondary prevention for cervical, other genital, and
oropharyngeal cancer. Although health state valuations
appropriate for modeled economic evaluations have been
undertaken for cervical HPV disease including cancer and
precancerous lesions [49,50] and for genital warts [51], there
is a paucity of information on health state valuations for other
HPV cancer states including oropharyngeal cancer. There is a
particular dearth of information on HPV-related health state
valuations for Aboriginal and Torres Strait Islander Australians.
Study Aims
The aims of this study were as follows:
1. To yield population estimates of the age-specific prevalence
of oncogenic genotypes of HPV in the mouth and
oropharynx of defined Aboriginal and Torres Strait Islander
populations (male and female). Hypothesis: The prevalence
of oral HPV among Aboriginal and Torres Strait Islander
Australians will be high compared with national-level
estimates.
2. Using preliminary data from Aim 1, and information on the
prevalence of other risk factors for oropharyngeal cancer
in the Aboriginal and Torres Strait Islander population, to
estimate burden of HPV-related oropharyngeal cancer
among Aboriginal and Torres Strait Islander men and
women. Hypothesis: The burden among Aboriginal and
Torres Strait Islanders of HPV and related oropharyngeal
cancer will be high.
3. To estimate the impact of HPV vaccination as currently
implemented on rates of cervical and oropharyngeal cancer
among Aboriginal and Torres Strait Islander Australians.
Hypothesis: HPV vaccination will, over time, reduce the
burden of cervical and oropharyngealcancer among
Aboriginals and Torres Strait Islanders.
4. To evaluate efficacy and cost-effectiveness of targeted
extended HPV vaccination among Aboriginal and Torres
Strait Islander Australians, incorporating the effectiveness
against both cervical cancer (in females) and oropharyngeal
cancer. Different upper age thresholds for targeted extension
will be considered. Hypothesis: Age-extended HPV
vaccination for Aboriginal and Torres Strait Islander
Australians will be efficacious; we will estimate an upper
age limit at which it would be cost-effective.
Methods
Study Design
Our overall study design will impose minimal impost on
Aboriginal and Torres Strait Islander participants. It involves
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testing for carriage of hrHPV in the mouth and oropharynx
among 1000 Aboriginal South Australians by simple saliva
collection, with follow-up at 12 and 24 months, collection of
sexual history at baseline, collection of information for
estimating utilities at baseline, genotyping the viruses, statistical
analysis (including cost-effectiveness modeling), data
interpretation and development of vaccination and clinical
therapeutic strategies to better communicate the benefits of HPV
vaccination and lifestyle changes in cancer prevention, and
approaches to take into account the preferences of Indigenous
people in prevention and management of cancer driven by the
Aboriginal community.
Ethical Approval
Ethics approval has been obtained from the University of
Adelaide Human Research Ethics Committee (H-2016-246).
Before being recruited, all participants will be required to sign
an informed consent form, which includes consent for the
authors to publish the findings in the peer-reviewed scientific
literature. The authors confirm that supporting data and material
in the study will be made available through Springer Nature’s
Data Support Services.
Study Population and Recruitment
We will recruit 1000 Aboriginal South Australian male and
female adults, with a focus on Port Augusta, Whyalla, Port
Lincoln, Mount Gambier, Ceduna, and Adelaide. Census data
indicate approximately 22,000 Aboriginal adults reside in these
areas. The investigators have a 13-year relationship with key
Aboriginal stakeholder groups in these locations, who are willing
and excited to be part of the study. Recruitment strategies will
be based on those successfully implemented in the past,
including the following: establishing service agreements with
key Aboriginal community-controlled health organizations,
liaising with community champions previously involved in our
research, and encouraging word-of-mouth spread of knowledge.
Inclusion and Exclusion Criteria
Participants will be aged 18+ years, identify as being Aboriginal
or Torres Strait Islander, and planning to live in South Australia
for the next 3 years. Participants not enrolled during the original
recruitment period will not be eligible to participate in the
follow-up phases.
Collection of Human Papillomavirus and
Oropharyngeal-Related Information
Permission to obtain sensitive information from participants
will be sought, with relevant information related to alcohol and
tobacco use, HPV diagnosis, health behaviors (including HPV
vaccination status and sexual behaviors), and social determinants
asked through a self-report questionnaire. Data will be collected
by experienced Aboriginal research officers.
Collection of Utilities Information
We will design a questionnaire for the utility study, in which
all 1000 participants taking part in the oral HPV prevalence
study will be asked to indicate preferences (rank and utility
scores) for 6 hypothetical states relating to oral HPV testing,
precursor oropharyngeal cancer, and early-stage oropharyngeal
cancer (including examinations and treatment). On the basis of
standard methods used in the development of utilities,
preferences for health states will be measured through ranking
(1 through to 6), followed by a 2-stage standard gamble. We
will focus on valuing the long-term oropharyngeal cancer health
state of the average patient who survives up to 5 years after
diagnosis and treatment, which is the most appropriate state for
modeling cost-effectiveness of prophylactic HPV vaccination.
We will seek to generate utility values for all cancer stages at
diagnosis. The process for developing the health states will
involve the following: (1) the most common stage(s) of
HPV-associated oropharyngeal cancer at diagnosis identified
from the literature; (2) the recommended treatment for the
relevant stages(s) of oropharyngeal cancer identified and
confirmed from published studies; and (3) the more common
long-term consequences (applying to ≥50% patients) in patients
surviving the initial treatment phase described based on the
literature, and subsequent refinement by clinical experts involved
in managing oropharyngeal cancer [52,53].
Collection of Oral Human Papillomavirus Data
All participants will be asked to provide a saliva sample using
a commercially available kit (Omnigene 501; DNA Genotek
Inc, Canada) from which microbial DNA for genotyping will
be extracted. This involves the participant: (a) not eating or
drinking for 30 min before collection; (b) spitting until 2 ml
reaches the fill line on the container (takes 2-3 min); (c) closing
the lid on the funnel (to release preservative liquid into tube);
(d) removing the funnel lid on the container; and (e) placing the
small cap on the tube and shaking the tube for 5 seconds. This
results in over 100 μg of DNA collection, which is sufficient
for the testing required. The sample can be kept at room
temperature (for up to 12 months) until collection by the
Aboriginal research assistants, who will send it to an appropriate
laboratory for analysis. Saliva samples will be collected at
baseline, 12 months, and 24 months.
Data Analysis
In brief, the analysis plan for each aim is described below.
Aim 1: To Yield Population Estimates of Oral Human
Papillomavirus in the Aboriginal and Torres Strait
Islander Population
DNA Extraction and Quality Check
Antonsson and colleagues have evaluated 3 different kits (all
semi-automated) for DNA extraction, namely, Promega’s
Maxwell-16 Viral Total Nucleic Acid Purification Kit,
QIAGEN’s QIAamp Mini Elute Virus Spin Kit, and QIAamp
Blood DNA Mini Kit (QIAcube). We will use the Promega
Maxwell viral kit for DNA extraction as the DNA yield and
quality was superior compared with the 2 other kits. β-globin
polymerase chain reaction (PCR) with the primers PCO3 and
PCO4 will be carried out on all samples to ensure that they
contain enough cells to detect human DNA, and that no PCR
inhibiting agents are present [54].
HPV Type Determination
We will analyze all samples with the optimized general primer
(GP)+PCR system that detects most mucosal HPV types and
all hrHPV types that have oncogenic potential in mucosal tissue
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[54]. All HPV DNA positive samples will be sequenced to
confirm viral DNA sequences. For the sequencing, HPV-positive
PCR products will be purified with the Agencourt AMPure PCR
purification kit in a magnetic 96-ring SPRIplate. Sequencing
reactions containing the purified PCR products together with
GP+primer and BigDye Terminator will be performed. Sequence
reactions will be purified with the Agencourt CleanSEQ
dye-terminator removal kit in a magnetic 96-ring SPRIplate.
Direct sequencing will be carried out initially. Samples with
multiple HPV types will be cloned before sequencing, with at
least 5 clones sequenced per sample. Sequence reactions will
be analyzed with an automated DNA sequencer (ABI model
3100). The DNA sequences will be compared with available
sequences in GenBank through the BLAST server. We have
chosen a standard PCR method, which has been used in several
projects by Antonsson and proven to be both reliable and
reproducible [4,55-57].
Specimen Variables
HPV status and genotypes found will be analyzed. The
genotypes will also be divided into low-risk (not found in cancer;
eg, HPV-6 and -11) and hrHPV types (found in cancer; eg,
HPV-16 and -18). As multiple HPV infections are likely,
incident infection will be defined as a new type-specific HPV
infection not detected in a previous sample. We will determine
the precision of HPV prevalence estimates obtainable with the
sample of 1000 in age- and sex-specific subgroups. We will
base these estimates on measurements in other populations by
age and sex, and then characterize 95% CIs obtainable in the
given sample size.
Aim 2: Using Preliminary Data From Aim 1, and
Information on Prevalence of Other Risk Factors, to
Estimate Burden of Human Papillomavirus-Related
Oropharyngeal Cancer Among Aboriginal and Torres
Strait Islander Australians
Sufficiently detailed information on oropharyngeal cancer rates
overall, or the proportion of oropharyngeal cancers which are
HPV-positive, are not available for the Indigenous population.
Therefore, these rates will be estimated using published data
on HPV-positive and HPV-negative oropharyngeal cancers in
the general population [27,58]. Each estimate will be scaled to
account for different risk factor prevalences. For HPV-positive
cancers, we will use our preliminary findings on the relative
prevalence of oral HPV in the Indigenous population compared
with that in the general population [57] to scale rates of
HPV-positive oropharyngeal cancer. Overall estimates of
oropharyngeal cancer will be compared with available published
data on the relative incidence of oropharyngeal cancer overall
in the Indigenous versus the general population to ensure
consistency [5].
Utilities and Costings
We will perform systematic reviews of utilities for
oropharyngeal cancer diagnosis, surveillance, surgery, and the
diagnosis/treatment of associated cancers. We will also perform
systematic reviews of complication rates and associated utilities
for surveillance and surgery. Aggregate costs for each step
involved in screening, diagnosis, family counseling, referral
and management pathways, and cancer diagnosis and treatment
will be collated using methods previously employed by Canfell
and colleagues for other cancer-related applications [59,60].
Briefly, detailed clinical pathways for current practice will be
described using relevant patterns of care studies and clinical
practice guidelines, and will take into account different patterns
of care/attendance for treatment among Aboriginal and Torres
Strait Islander Australians. Item costs of the component services
will be obtained from the Medicare Benefit Schedule Online
for outpatient medical services, the latest available National
Hospital Cost Data Collection Round for inpatient services and
the Pharmaceutical Benefits Schedule Online.
Aim 3: To Evaluate the Impact of Human Papillomavirus
Vaccination as Currently Implemented on
Oropharyngeal and Cervical Cancer Rates Among
Aboriginal and Torres Strait Islander Australians
The results of Aim 2 will feed into an existing model of HPV
transmission, vaccination, and natural history developed by
Canfell and colleagues through previous grants from Australia’s
National Health and Medical Research Council (NHMRC). This
model has been used extensively for evaluations around HPV
and cervical cancer prevention in government-commissioned
reports and in 20 journal publications. In the proposed study,
this model will be further tailored to the Aboriginal and Torres
Strait Islander population. The developed model will be used
to make detailed predictions of the impact of HPV vaccination
over time on oropharyngeal and cervical cancer among
Aboriginal and Torres Strait Islander Australians, including
under a range of age ranges for vaccination and dose/uptake
assumptions. This will be based on the burden of
HPV-attributable oropharyngeal and cervical cancer in the
Indigenous population estimated in Aim 2, which will take into
account different tobacco smoking prevalence or varied
attributable fraction to allow for the higher proportion of
HPV-negative tumors in the Indigenous population. Estimates
of HPV vaccine uptake in Aboriginal and Torres Strait Islander
Australians will be used, in conjunction with available data on
HPV vaccine impact in Aboriginal and Torres Strait Islander
populations or precursor/proxy outcomes, such as prevalence
of infection with vaccine-included types and anogenital warts.
We will validate model predictions against these previously
reported outcomes [41,42].
Aim 4: To Evaluate Efficacy and Cost-Effectiveness of
Targeted Extended Human Papillomavirus Vaccination
on Oropharyngeal Cancer Among Aboriginal and Torres
Strait Islanders, Incorporating the Effectiveness Against
Both Cervical Cancer (in Females) and Oropharyngeal
Cancer
We will use data from the literature review and utility
estimations in Aim 2 to inform model assumptions on the
demographics and risk profile of the population. To achieve
higher coverage in this group, we will estimate impact and
cost-effectiveness of funding extended catch-up vaccination for
Aboriginal and Torres Strait Islander Australians (for those who
did not receive the vaccine through the school-based program).
A range of potential extended catch-up strategies will be
considered, eg, funding HPV vaccination for females ± males
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aged up to 18, 25, 30, or 45 years who have not already received
a full course. We will consider both first and second generation
HPV vaccines and also consider strategies involving
revaccination of individuals who have already received the first
generation vaccine with the second generation vaccine. We will
also consider different potential delivery mechanisms, eg, via
Aboriginal health services and/or other community providers.
For each analysis, a large “virtual” sample of the Aboriginal
and Torres Strait Islander population will be simulated. Each
evaluation will then use all fitted parameter sets to derive a
baseline result and 95% CI. These evaluations will simulate
10,000 individuals. All evaluations will be accompanied by
extensive sensitivity analysis, using one-way and probabilistic
sensitivity analysis techniques that will take into account the
full range of identified fitted parameter sets. For each strategy,
we will calculate a number of measures of effectiveness,
including change in cancer incidence, mortality, life years saved,
and quality-adjusted life years gained. We will also estimate
absolute case numbers based on population projections available
by age, sex, and calendar year for ASTI Australians. We will
assess morbidity via calculation of quality-adjusted life years
and calculate complication numbers from surveillance and
surgery. We will take into account varying rates of attendance
for treatment in the Indigenous population [61], but consider a
range of assumptions in sensitivity analysis. We will provide
detailed predictions of health resources utilization, including
numbers of tests, biopsies, and treatments. We will assess costs
of diagnosis, surveillance and cancer treatment, and the total
budget impact for each year from 2017 to 2030. We will
calculate incremental cost-effectiveness ratios for both life years
saved and quality-adjusted life years. If results suggest that
extended HPV vaccination among Aboriginal and Torres Strait
Islander Australians is not cost-effective at any age threshold,
we will perform threshold analysis to determine the cost at
which extended HPV vaccination to different upper age
thresholds becomes cost-effective.
Ethical Approval
Ethical approval for this study has been obtained by the
University of Adelaide Human Research Ethics Committee
(H-2016-246).
Results
Participant recruitment for this study commenced in February
2018 and enrollment is ongoing. The first results are expected
to be submitted for publication in 2019.
Discussion
Study Overview
Oropharyngeal cancer is an important cancer affecting
Aboriginal and Torres Strait Islander Australians at a higher
rate than other Australians. Infection with hrHPV is a significant
risk factor for oropharyngeal cancer. HPV vaccination is
effective against the 2 most common types of hrHPV, with some
promise that current vaccines may prevent oral infections
(potentially reducing the risk of oropharyngeal cancer). Given
the elevated risk of HPV-related cancers in this group, it may
be reasonable to extend the comparatively brief timeframe (when
aged 12-13 years) in which Aboriginal and Torres Strait Islander
Australians can access an otherwise costly vaccine via public
funding. The project will have a number of important outcomes.
Synthesis of evidence will directly support estimates of the
burden of oropharyngeal cancer among Aboriginal and Torres
Strait Islander Australians and the effectiveness and
cost-effectiveness of prevention. This will be important for
health services planning, and for Aboriginal health worker and
patient education. The project provides a key example of how
carefully calibrated, data-driven disease models can integrate
with Aboriginal community views and expectations to estimate
disease burden and to guide policy decisions.
Study Strengths
The strengths of the study include it being the first to obtain
and link all the information on cervical and oropharyngeal
cancers via modeling (possibly in any population but certainly
for the Australian Aboriginal and Torres Strait Islander
population) and the focus on engagement, enabling community
and individual preferences to play a large role in decision
making for Aboriginal and Torres Strait Islander Australians.
Burger and colleagues investigated the impact of HPV on 6
HPV-associated cancers, including cervical and oropharyngeal
cancer, among 5 ethnic groups in the United States, one of which
included Native American/Alaskan Natives [62].
Study Limitations
The limitations include the sample frame for oral HPV
prevalence assessment being pragmatic, ie, utilizing convenience
sampling methodology rather than attempting to be
representative. Although there is a risk of sampling bias, the
efforts required to obtain a representative sample are recognized
as being both expensive and time-consuming [63]. Additionally,
it is recognized that oral HPV measurement through saliva
sampling is blunt as it does not provide a direct measure of HPV
exposure at each potential cancer site. Finally, as in any modeled
assessment, assumptions about future vaccination and screening
coverage need to be made, but we remain committed to engaging
the Aboriginal and Torres Strait Islander community in
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hrHPV: high-risk human papillomavirus
NHMRC: National Health and Medical Research Council
NHVP: National HPV Vaccination Program
PCO3: (5’CTTCTGACACAACTGTGTTCACTAGC3’) oligonucleotide
PCO4: (5’TCACCACAACTTCATCCACGTTCACC3’) oligonucleotide
PCR: polymerase chain reaction
Edited by G Eysenbach; submitted 25.03.18; peer-reviewed by C Schnelle; comments to author 31.03.18; revised version received
03.04.18; accepted 04.04.18; published 08.06.18
Please cite as:
Jamieson L, Garvey G, Hedges J, Mitchell A, Dunbar T, Leane C, Hill I, Warren K, Brown A, Ju X, Roder D, Logan R, Johnson N,
Smith M, Antonsson A, Canfell K
Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related
Human Papillomavirus and Cost-Effectiveness of Prevention




©Lisa Jamieson, Gail Garvey, Joanne Hedges, Amanda Mitchell, Terry Dunbar, Cathy Leane, Isaac Hill, Kate Warren, Alex
Brown, Xiangqun Ju, David Roder, Richard Logan, Newell Johnson, Megan Smith, Annika Antonsson, Karen Canfell. Originally
published in JMIR Research Protocols (http://www.researchprotocols.org), 08.06.2018. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research
Protocols, is properly cited. The complete bibliographic information, a link to the original publication on
http://www.researchprotocols.org, as well as this copyright and license information must be included.
JMIR Res Protoc 2018 | vol. 7 | iss. 6 | e10503 | p.11http://www.researchprotocols.org/2018/6/e10503/
(page number not for citation purposes)
Jamieson et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
